IMTX
Immatics NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
—
EPS
$-1.84
Beta
1.34
52W High
$12.41
52W Low
$3.74
50-Day MA
$9.84
200-Day MA
$8.56
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immatics NV
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
Fundamentals
| Revenue (TTM) | $48.27M |
| Gross Profit (TTM) | $-135.57M |
| EBITDA | $-172.88M |
| Operating Margin | -196.80% |
| Return on Equity | -37.10% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $0.39 |
| Book Value | $4.18 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 28.48 |
| EV/Revenue | 15.45 |
| EV/EBITDA | 7.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -64.90% |
| Shares Outstanding | $134.10M |
| Float | $69.33M |
| % Insiders | 17.92% |
| % Institutions | 76.27% |
Analyst Ratings
Consensus ($18.75 target)
9
BuyData last updated: 4/8/2026